vs
Side-by-side financial comparison of CG Oncology, Inc. (CGON) and OLB GROUP, INC. (OLB). Click either name above to swap in a different company.
CG Oncology, Inc. is the larger business by last-quarter revenue ($2.3M vs $1.8M, roughly 1.3× OLB GROUP, INC.). OLB GROUP, INC. runs the higher net margin — -83.7% vs -1779.0%, a 1695.3% gap on every dollar of revenue. On growth, CG Oncology, Inc. posted the faster year-over-year revenue change (409.2% vs -35.2%).
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
OLB Group, Inc. is a global financial technology provider offering omnichannel payment processing solutions, e-commerce enablement tools, and digital banking services for small and medium-sized enterprises across North America, Europe, and key Asia-Pacific markets. Its core segments include merchant services, crypto payment integration, and cloud-based business management platforms.
CGON vs OLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3M | $1.8M |
| Net Profit | $-41.3M | $-1.5M |
| Gross Margin | — | — |
| Operating Margin | -2097.3% | -83.7% |
| Net Margin | -1779.0% | -83.7% |
| Revenue YoY | 409.2% | -35.2% |
| Net Profit YoY | -29.9% | 67.5% |
| EPS (diluted) | $-0.52 | $-0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3M | $1.8M | ||
| Q3 25 | $1.7M | $2.3M | ||
| Q2 25 | $0 | $2.3M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $456.0K | $2.7M | ||
| Q3 24 | — | $3.1M | ||
| Q2 24 | — | $3.5M | ||
| Q1 24 | $529.0K | $3.5M |
| Q4 25 | $-41.3M | $-1.5M | ||
| Q3 25 | $-43.8M | $-1.2M | ||
| Q2 25 | $-41.4M | $-2.1M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | $-31.8M | $-4.6M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | $-16.9M | $-2.4M |
| Q4 25 | -2097.3% | -83.7% | ||
| Q3 25 | -3069.0% | -49.1% | ||
| Q2 25 | — | -74.8% | ||
| Q1 25 | — | -36.6% | ||
| Q4 24 | -8344.1% | -166.0% | ||
| Q3 24 | — | -52.9% | ||
| Q2 24 | — | -74.3% | ||
| Q1 24 | -4247.4% | -82.6% |
| Q4 25 | -1779.0% | -83.7% | ||
| Q3 25 | -2629.5% | -50.8% | ||
| Q2 25 | — | -93.7% | ||
| Q1 25 | — | -46.9% | ||
| Q4 24 | -6973.7% | -167.1% | ||
| Q3 24 | — | -52.9% | ||
| Q2 24 | — | -75.2% | ||
| Q1 24 | -3200.8% | -67.8% |
| Q4 25 | $-0.52 | $-0.48 | ||
| Q3 25 | $-0.57 | $-0.13 | ||
| Q2 25 | $-0.54 | $-0.66 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | $-0.47 | $-3.55 | ||
| Q3 24 | — | $-0.92 | ||
| Q2 24 | — | $-1.49 | ||
| Q1 24 | $-0.36 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $742.2M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $752.6M | $4.6M |
| Total Assets | $791.6M | $12.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $742.2M | — | ||
| Q3 25 | $680.3M | — | ||
| Q2 25 | $661.1M | — | ||
| Q1 25 | — | $29.3K | ||
| Q4 24 | $742.0M | $27.4K | ||
| Q3 24 | — | $41.3K | ||
| Q2 24 | — | $53.3K | ||
| Q1 24 | $566.5M | $3.3K |
| Q4 25 | $752.6M | $4.6M | ||
| Q3 25 | $687.6M | $5.3M | ||
| Q2 25 | $670.4M | $6.4M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $733.4M | $3.2M | ||
| Q3 24 | — | $6.7M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | $568.9M | $11.0M |
| Q4 25 | $791.6M | $12.3M | ||
| Q3 25 | $729.9M | $12.2M | ||
| Q2 25 | $701.4M | $12.4M | ||
| Q1 25 | — | $12.5M | ||
| Q4 24 | $754.8M | $12.7M | ||
| Q3 24 | — | $15.9M | ||
| Q2 24 | — | $16.6M | ||
| Q1 24 | $579.1M | $18.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-36.2M | $-1.3M |
| Free Cash FlowOCF − Capex | $-36.2M | — |
| FCF MarginFCF / Revenue | -1560.0% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-124.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-36.2M | $-1.3M | ||
| Q3 25 | $-38.9M | $-115.5K | ||
| Q2 25 | $-28.0M | $-1.0M | ||
| Q1 25 | — | $-155.8K | ||
| Q4 24 | $-20.7M | $-2.6M | ||
| Q3 24 | — | $-376.7K | ||
| Q2 24 | — | $-785.5K | ||
| Q1 24 | $-26.0M | $-424.7K |
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-39.0M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-20.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | -1560.0% | — | ||
| Q3 25 | -2340.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4577.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -4919.5% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 45.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CGON
Segment breakdown not available.
OLB
| Transaction And Processing Fees | $1.7M | 94% |
| Other | $99.2K | 6% |
